Elder to strengthen existing brands following sale to Torrent

18 July 2014

Indian drugmaker Elder Pharma (BSE:532322) has said it plans to strengthen its existing brands including Eldervit and Somazina, and build on its domestic business of anti-infectives, strengthen its in-license portfolio and grow its business in the UK and Europe.

This follows the company’s sale of its branded drugs business in India and Nepal to Torrent Pharmaceuticals, meaning around 30 brands moved across to Torrent after the March 31 deal.

It has appointed consulting firm Deloitte to help this strengthening and restructure the organization. Elder’s brand Eldervit and in-licensed brand Phydomega have been achieving healthy sales and the company expects them to be the major contributors to future success. Its anti-infective division has contributed more than 10% to the company’s total revenue and has been registering annual growth in excess of 12%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK